Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non–small cell lung cancer and melanoma brain metastases

Background Prior literature has suggested synergy between immune checkpoint therapy (ICT) and radiotherapy (RT) for the treatment of brain metastases (BrM), but to the authors' knowledge the optimal timing of therapy to maximize this synergy is unclear. Methods A total of 199 patients with mela...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2020-12, Vol.126 (24), p.5274-5282
Hauptverfasser:	Qian, Jack M., Martin, Allison M., Martin, Kate, Hammoudeh, Lubna, Catalano, Paul J., Hodi, F. Stephen, Cagney, Daniel N., Haas‐Kogan, Daphne A., Schoenfeld, Jonathan D., Aizer, Ayal A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged anti‐cytotoxic T‐lymphocyte–associated protein 4 (anti–CTLA‐4) therapy anti‐programmed cell death protein 1 (anti–PD‐1) therapy Brain Brain cancer brain metastases Brain Neoplasms - secondary Brain Neoplasms - therapy Carcinoma, Non-Small-Cell Lung - therapy Chemoradiotherapy Clinical trials Disease Progression Female Hazard assessment Health hazards Humans Immune checkpoint Immune Checkpoint Inhibitors Immunotherapy Lung cancer Lung Neoplasms - therapy Male Melanoma Melanoma - secondary Melanoma - therapy Metastases Metastasis Middle Aged Neoplasm Recurrence, Local Non-small cell lung carcinoma non–small cell lung cancer (NSCLC) Oncology Proportional Hazards Models Prospective Studies Radiation therapy radiotherapy Statistical analysis Statistical models Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!